全文获取类型
收费全文 | 72267篇 |
免费 | 5793篇 |
国内免费 | 340篇 |
学科分类
医药卫生 | 78400篇 |
出版年
2023年 | 311篇 |
2021年 | 1252篇 |
2020年 | 818篇 |
2019年 | 1149篇 |
2018年 | 1384篇 |
2017年 | 977篇 |
2016年 | 1084篇 |
2015年 | 1292篇 |
2014年 | 2012篇 |
2013年 | 3136篇 |
2012年 | 4227篇 |
2011年 | 4610篇 |
2010年 | 2605篇 |
2009年 | 2424篇 |
2008年 | 4416篇 |
2007年 | 4603篇 |
2006年 | 4442篇 |
2005年 | 4510篇 |
2004年 | 4231篇 |
2003年 | 3815篇 |
2002年 | 3781篇 |
2001年 | 1048篇 |
2000年 | 956篇 |
1999年 | 1019篇 |
1998年 | 862篇 |
1997年 | 709篇 |
1996年 | 512篇 |
1995年 | 581篇 |
1994年 | 555篇 |
1993年 | 534篇 |
1992年 | 749篇 |
1991年 | 754篇 |
1990年 | 633篇 |
1989年 | 623篇 |
1988年 | 605篇 |
1987年 | 594篇 |
1986年 | 549篇 |
1985年 | 618篇 |
1984年 | 579篇 |
1983年 | 528篇 |
1982年 | 607篇 |
1981年 | 514篇 |
1980年 | 547篇 |
1979年 | 401篇 |
1978年 | 402篇 |
1977年 | 390篇 |
1976年 | 327篇 |
1975年 | 358篇 |
1974年 | 305篇 |
1973年 | 292篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
Rajendrababu Sharmila Puthuran George Varghese Alia Laxmi Ananya Uduman Mohammed Sithiq Wijesinghe Hiruni Kaushalya 《International ophthalmology》2022,42(8):2609-2618
International Ophthalmology - To investigate the efficacy and safety of non-valved Aurolab aqueous drainage implant (AADI) surgery combined with phacoemulsification in eyes with refractory glaucoma... 相似文献
3.
Ki-Yong An Andria R. Morielli Dong-Woo Kang Christine M. Friedenreich Donald C. McKenzie Karen Gelmon John R. Mackey Robert D. Reid Kerry S. Courneya 《International journal of cancer. Journal international du cancer》2020,146(1):150-160
The Combined Aerobic and Resistance Exercise (CARE) Trial compared different types and doses of exercise performed during breast cancer chemotherapy. Here, we report the longer-term follow-up of patient-reported outcomes, health-related fitness and exercise behavior at 6, 12 and 24 months postintervention. A multicenter trial in Canada randomized 301 breast cancer patients initiating chemotherapy to thrice weekly, supervised exercise consisting of a standard dose of 25–30 min of aerobic exercise (STAN; n = 96), a higher dose of 50–60 min of aerobic exercise (HIGH; n = 101) or a combined dose of 50–60 min of aerobic and resistance exercise (COMB; n = 104) performed for the duration of chemotherapy (median of 17 weeks). Primary outcomes were patient-reported outcomes including quality of life, cancer-related symptoms and psychosocial outcomes. Secondary outcomes were objective health-related fitness (assessed at 12 months only) and self-reported exercise behavior. A total of 269 (89.4%) participants completed patient-reported outcomes at all three follow-up time points and 263 (87.4%) completed the health-related fitness assessment at 12-month follow-up. COMB was significantly superior to (i) STAN for sleep quality at 6-month follow-up (p = 0.027); (ii) HIGH for upper body muscular endurance at 12-month follow-up (p = 0.020); and (iii) HIGH for meeting the resistance exercise guideline at 6-month follow-up (p = 0.006). Moreover, self-reported meeting of the combined exercise guideline during follow-up was significantly associated with better patient-reported outcomes and health-related fitness. Performing combined exercise during and after breast cancer chemotherapy may result in better longer-term patient-reported outcomes and health-related fitness compared to performing aerobic exercise alone. 相似文献
4.
I. R. Reid 《Journal of internal medicine》2015,277(6):690-706
There is an increasing number of effective therapies for fracture prevention in adults at risk of osteoporosis. However, shortcomings in the evidence underpinning our management of osteoporosis still exist. Evidence of antifracture efficacy in the groups of patients who most commonly use calcium and vitamin D supplements is lacking, the safety of calcium supplements is in doubt, and the safety and efficacy of high doses of vitamin D give cause for concern. Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures. However, most trials provide little information regarding long‐term efficacy or safety. A particular concern at present is the possibility that oral bisphosphonates might cause atypical femoral fractures. Observational data suggest that the incidence of this type of fracture increases steeply with duration of bisphosphonate use, resulting in concern that the benefit–risk balance may become negative in the long term, particularly in patients in whom the osteoporotic fracture risk is not high. Therefore, reappraisal of ongoing use of bisphosphonates after about 5 years is endorsed by expert consensus, and ‘drug holidays’ should be considered at this time. Further studies are needed to guide clinical practice in this area. 相似文献
5.
La Rosa Mauricio Omere Chasey Redfern Tiffany Abdelwahab Mahmoud Spencer Nicholas Villarreal Josephine Olson Gayle Saade George R. Saad Antonio F. 《Archives of gynecology and obstetrics》2020,301(1):69-73
Archives of Gynecology and Obstetrics - The objective of this study was to determine if high-dose antibiotic prophylaxis with cefazolin decreases the risk of surgical site infection (SSI) after a... 相似文献
6.
7.
8.
9.
10.
Katja Kobow Christopher A. Reid Erwin A. van Vliet Albert J. Becker Gemma L. Carvill Alica M. Goldman Shinichi Hirose Iscia Lopes-Cendes Hela Mrabet Khiari Annapurna Poduri Michael R. Johnson David C. Henshall 《Epileptic Disord》2020,22(2):127-141
Epigenetics refers broadly to processes that influence medium to long‐term gene expression by changing the readability and accessibility of the genetic code. The Neurobiology Commission of the International League Against Epilepsy (ILAE) recently convened a Task Force to explore and disseminate advances in epigenetics to better understand their role and intersection with genetics and the neurobiology of epilepsies and their co‐morbidities, and to accelerate translation of these findings into the development of better therapies. Here, we provide a topic primer on epigenetics, explaining the key processes and findings to date in experimental and human epilepsy. We review the growing list of genes with epigenetic functions that have been linked with epilepsy in humans. We consider potential practical applications, including using epigenetic signals as biomarkers for tissue‐ and biofluid‐based diagnostics and the prospects for developing epigenetic‐based treatments for epilepsy. We include a glossary of terms, FAQs and other supports to facilitate a broad understanding of the topic for the non‐expert. Last, we review the limitations, research gaps and the next challenges. In summary, epigenetic processes represent important mechanisms controlling the activity of genes, providing opportunities for insight into disease mechanisms, biomarkers and novel therapies for epilepsy. 相似文献